TD Asset Management
BCAX

TD Asset Management’s Bicara Therapeutics BCAX Stock Holding History

TD Asset Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.75M Sell
261,118
-8,600
-3% -$192K 0.01% 713
2026
Q1 		$5.36M Buy
269,718
+25,092
+10% +$432K ﹤0.01% 781
2025
Q4 		$4.12M Buy
244,626
+59,644
+32% +$1.02M ﹤0.01% 837
2025
Q3 		$2.92M Sell
184,982
-39,556
-18% -$443K ﹤0.01% 886
2025
Q2 		$2.09M Buy
224,538
+93,600
+71% +$1.12M ﹤0.01% 923
2025
Q1 		$1.71M Buy
130,938
+28,518
+28% +$379K ﹤0.01% 1001
2024
Q4 		$1.78M Hold
102,420
– – ﹤0.01% 1038
2024
Q3 		$2.61M Buy
+102,420
New +$2.61M ﹤0.01% 947

Other funds holding BCAX

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

TD Asset Management's BCAX Position: Q2 2026 in Review

TD Asset Management reduced its Bicara Therapeutics (BCAX) stake by 3.2% in Q2 2026, selling an estimated $192K and leaving 261,118 shares worth $7.75M. The position accounts for 0.01% of the portfolio, ranked #713.

TD Asset Management first reported a position in BCAX in Q3 2024 and has held it in 8 quarters since. 112 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • TD Asset Management held 261,118 shares of Bicara Therapeutics worth $7.75M as of Q2 2026.
  • TD Asset Management sold 8,600 Bicara Therapeutics shares in Q2 2026, an estimated $192K.
  • Bicara Therapeutics made up 0.01% of TD Asset Management's portfolio in Q2 2026, its #713 holding.
  • TD Asset Management first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 112 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.